Klin Farmakol Farm. 2025;39(4):245-248 | DOI: 10.36290/far.2025.064

Selection of an appropriate urinary spasmolytic in a geriatric patient

Lada Feřtová1, 2, Barbora Brezinová1, 2, 3, Jaroslava Červeňová1, 2
1 Oddělení klinické farmacie Lochotín, Fakultní nemocnice Plzeň
2 Lékařská fakulta v Plzni, Univerzita Karlova
3 Katedra sociální a klinické farmacie, Farmaceutická fakulta v Hradci Králové, Univerzita Karlova

The selection of an appropriate medication for a geriatric patient is a complex process that requires careful consideration of several factors, such as the presence of all medications in the patient's pharmacological history, age-related changes in pharmacokinetics and pharmacodynamics, the patient's functional status, and comorbidities. Special attention should also be given to the medication regimen itself (including dosage forms), ensuring maximum support for patient adherence to pharmacotherapy. This case study discusses an individualized approach to urinary spasmolytic selection in a multimorbid geriatric patient. This article provides comparison of different drug classes, as well as individual molecules.

Keywords: geriatric pharmacotherapy, urinary incontinence, urinary spasmolytics.

Received: July 29, 2025; Revised: October 24, 2025; Accepted: October 24, 2025; Published: December 22, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Feřtová L, Brezinová B, Červeňová J. Selection of an appropriate urinary spasmolytic in a geriatric patient. Klin Farmakol Farm. 2025;39(4):245-248. doi: 10.36290/far.2025.064.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Topinková E. Farmakoterapie urgentní inkontinence a hyperaktivního měchýře u seniorů. Urol. praxi 2017;18(4): 148-153. Go to original source...
    2. Drábková P. Hyperaktivní močový měchýř ve stáří jako ošetřovatelský problém. Urol. praxi. 2021;22(3):155-158. Go to original source...
    3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178. Go to original source... Go to PubMed...
    4. Horčička L, Topinková E. Hyperaktivní močový měchýř u starších pacientek: zvláštnosti léčby a lékové interakce. Vnitřní lékařství 2018;64(11):1085-1090. Go to original source...
    5. Tůma J, Porovnání účinnosti a vedlejších účinků anticholinergik v léčbě syndromu hyperaktivního močového měchýře. Urol. praxi. 2021;22(3):115-119. Go to original source...
    6. Eglen RM, Choppin A, Watson N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci. 2001;22(8):409-414. Go to original source... Go to PubMed...
    7. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol. 1996;10(1):69-99. Go to original source... Go to PubMed...
    8. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279-290. Go to original source...
    9. Fialová D. Specifické rysy geriatrické farmakoterapie z pohledu farmakokinetických a farmakodynamických změn ve stáří. Remedia 2009.
    10. Dengler KL, High RA, Moga DC, et al. Overactive Bladder and Cognitive Impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report. Urogynecology (Phila). 2023;29(1S Suppl 1):S1-S19. Go to original source... Go to PubMed...
    11. ABC kalkulátor [online]. Available from: https://www.acbcalc.com/.
    12. Ressner P, Konrád J, Bártlová P. Delirium u geriatrických nemocných. Neurol. praxi 2011;12(5):311-316.
    13. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs. 2004;64(21):2433-2446. Go to original source... Go to PubMed...
    14. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous systém. J Clin Pharmacol. 2001;41(6):636-644. Go to original source... Go to PubMed...
    15. Scarpignato C, Pelosini I. Treatment of overactive bladder: are all antimuscarinics the same? Drugs. 2008;68(2):245-264.
    16. Stangier J, Schug BS, Stähle H, Roth W. Pharmacokinetics and pharmacodynamics of trospium chloride in healthy volunteers after single doses. Br J Clin Pharmacol. 2008; 65(5):664-673.
    17. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004;25(8):423-429. Go to original source... Go to PubMed...
    18. Zinner N. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opin Pharmacother 2007;8(4):511-523. Go to original source... Go to PubMed...
    19. SmPC Uroxal, www.sukl.cz.
    20. SmPC Mictonetten, Mictonorm, www.suk.cz.
    21. SmPC Folinar, www.sukl.cz.
    22. SmPC Emselex, www.sukl.cz.
    23. SmPC Toviaz, www.sukl.cz.
    24. SmPC Spasmed, www.sukl.cz.Topinková E, Fialová D. Nová verze STOPP­‑START kritérií 2023 jako vhodný nástroj ke zlepšení lékové preskripce u starších pacientů. Vnitř Lék. 2023;69(8):516-524. Go to original source...
    25. Michel MC, Wetterauer U, Vogel M, Rosette J. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study, Drug Saf 2008;31(6):505-514. Go to original source... Go to PubMed...
    26. Chapple CH, Cardozo L, Nitti V, et al. Mirabegron in overactive bladder: a review off efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17-30. Go to original source... Go to PubMed...
    27. Wagg A, Nitti V, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics, Curr Med Res Opin. 2016;32(4):621-638. Go to original source... Go to PubMed...
    28. Enemchukwu E. Beta 3 agonists: A "much-needed alternative" for patients with OAB, Urol. Times Innovation Celebration: Expert Insights: Episode 17.
    29. White W, Siddiqui E, Tat T, et al. Cardiovascular safaty of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens. 2018;12(11):768-778. Go to original source... Go to PubMed...
    30. Betmiga: Summary of product characteristics (SPC). Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002388/WC500137309.pdf.
    31. Lee J, Moy S, Meijer J, et al. Role of cytochrome P450 isoenzymes 3A and 2D6 in the in vivo metabolism od mirabegron, a β3-adrenoceptor agonist. Clin Drug Investig. 2013;33(6):429-440. Go to original source... Go to PubMed...
    32. Samer CF, Desmeules JA, Dayer P. Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics. Per Med. 2006;3(3):239-269. Go to original source... Go to PubMed...
    33. Keating GM. Mirabegron: a review of its use in patients with overactive bladder. Drugs. 2013;73(11):1213-1225. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.